HealthTab™ to Offer Abbott’s i-STAT Alinity™, Expanding Chronic Disease Testing to Select Community Pharmacies in Canada
November 23 2021 - 6:30AM
Avricore Health Inc. (TSXV:
AVCR, OTC: AVCRF) (“Avricore Health” or the “Company”) is pleased
to announce the signing of a non-exclusive, pilot supplier
distribution agreement in Canada between HealthTab™ Inc., a wholly
owned subsidiary, and Abbott, the global healthcare company, with
respect to the handheld blood chemistry analyzer, i-STAT Alinity.
The agreement allows HealthTab to distribute Abbott’s
point-of-care i-STAT Alinity and its associated tests for
creatinine in Canadian pharmacies to better support patients with
important information about their renal function.
“Understanding renal function in patients at risk from or
already living with chronic disease is critical,” said Hector
Bremner, CEO of Avricore Health. “With i-STAT Alinity and its
associated test for creatinine, healthcare professionals can obtain
results in approximately two minutes to detect elevated levels of
creatinine that are associated with abnormal renal function.”
Bringing high-quality point-of-care testing to pharmacists,
HealthTab deployed Afinion 2 in select Shoppers Drug Mart
pharmacies earlier this year as part of an initiative to screen for
and support patients living with diabetes. Also available as part
of the in-pharmacy platform is Abbott’s ID NOW product, a molecular
point-of-care instrument offering real-time detection of viruses,
including COVID-19, RSV and influenza.
About HealthTab™
HealthTab™ is a turnkey point-of-care testing solution that
combines best-in-class point-of-care technologies with a secure,
cloud-based platform for tackling pressing global health issues.
With just a few drops of blood from a finger prick, the system
generates lab-accurate results on the spot and data is reported in
real time. The test menu includes up to 23 key biomarkers for
screening and managing chronic diseases, such as diabetes and heart
disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also
recently added capabilities for bacterial and viral tests, such as
strep and COVID-19. The HealthTab™ network model is unlike anything
in pharmacy today. It gives knowledgeable and trusted pharmacists a
greater role in primary care delivery, while empowering patients to
take more control of their health. It also reduces costs and
waiting times and provides many potential revenue streams including
equipment leasing & consumables, direct access testing, disease
prevention & management programs, sponsored health programs,
decentralized clinical trials, real world data (RWD) sets, and
third-party app integration through API.
About Avricore Health
Inc.Avricore Health Inc. (TSXV: AVCR) is a pharmacy
service innovator focused on acquiring and developing early-stage
technologies aimed at moving pharmacy forward. Through its flagship
offering HealthTab™, a wholly owned subsidiary, the company’s
mission is to make actionable health information more accessible to
everyone by creating the world’s largest network of rapid testing
devices in community pharmacies.
Contact:Avricore Health
Inc. Hector
Bremner, CEO 604-773-8943
info@avricorehealth.com www.avricorehealth.com
Cautionary Note Regarding
Forward-Looking Statements Information in this press
release that involves Avricore Health's expectations, plans,
intentions or strategies regarding the future are forward-looking
statements that are not facts and involve a number of risks and
uncertainties. Avricore Health generally uses words such as
"outlook," "will," "could," "would," "might," "remains," "to be,"
"plans," "believes," "may," "expects," "intends," "anticipates,"
"estimate," "future," "positioned," "potential," "project,"
"remain," "scheduled," "set to," "subject to," "upcoming," and
similar expressions to help identify forward-looking statements. In
this press release, forward-looking statements include statements
regarding: the completion of the placement and the expected timing
thereof and the Company's expected use of proceeds from the
placement; the unique features that the HealthTab™ platform offers
to pharmacists and patients. Forward-looking statements reflect the
then-current expectations, beliefs, assumptions, estimates and
forecasts of Avricore Health's management. The forward-looking
statements in this press release are based upon information
available to Avricore Health as of the date of this press release.
Forward-looking statements believed to be true when made may
ultimately prove to be incorrect. These statements are not
guarantees of the future performance of Avricore Health and are
subject to a number of risks, uncertainties and other factors, some
of which are beyond its control and may cause actual results to
differ materially from current expectations, including without
limitation: failure to meet regulatory requirements; changes in the
market; potential downturns in economic conditions; and other risk
factors described in Avricore's public filings. These
forward-looking statements speak only as of the date on which they
are made, and the Company undertakes no obligation to update them
publicly to reflect new information or the occurrence of future
events or circumstances, unless otherwise required to do so by
law.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy.
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avricore Health (TSXV:AVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024